- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01026090
Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)
A Phase IV, Double-blind, Placebo-controlled, Canadian Multicentre Study Comparing Two Treatment Strategies of Dronedarone Administration Following ELECTive caRdioversion for Prevention of Symptomatic Atrial Fibrillation (AF) Recurrence
Primary Objective:
To determine whether daily administration of dronedarone started 5-7 days before cardioversion is superior to dronedarone started only after cardioversion with respect to the absence of symptomatic, ECG confirmed, atrial fibrillation (AF) recurrence over 6 months in adult patients with persistent AF, for whom cardioversion is clinically indicated and planned to reduce symptoms and antiarrhythmic treatment is clinically indicated to reduce the risk of cardiovascular hospitalization due to AF.
Secondary Objectives:
Main Secondary :
- To assess the number of symptomatic AF recurrences/patient/6 months with and without ECG confirmation;
- To assess characteristics of symptomatic AF recurrence in the two treatment arms (frequency, duration of episodes, type, number, and severity of AF symptoms per patient);
- To compare the rates of early recurrences of AF between the two treatment strategies;
Other secondary:
- To assess whether there is a difference in proportion of patients with symptomatic AF recurrences (with and without ECG confirmation) between the two treatment strategies;
- To assess whether there is a difference in number of electrical cardioversions per patient between the two treatment strategies;
- To assess the impact of the two strategies on number of shocks, cumulative amount of energy delivered, shock failure, and immediate success of cardioversion;
- To assess whether there is a difference in rate of cardiovascular (CV) hospitalizations and length of hospital stay between the two treatment strategies;
- To assess whether there is a difference in quality of life between the two treatment strategies.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study period of approximatively 6 months consisted in:
- Double-blind treatment period (placebo or dronedarone) for 5-7 days prior to cardioversion;
- Electrical cardioversion;
- Open-label treatment period with dronedarone for 6 months after cardioversion.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Abbotsford, Canada, V2S3N5
- Investigational Site Number 1240033
-
Barrie, Canada, L4M4S5
- Investigational Site Number 1240026
-
Calgary, Canada, T2E7C5
- Investigational Site Number 1240050
-
Cambridge, Canada, N1R6V6
- Investigational Site Number 1240010
-
Edmonton, Canada, T5H4B9
- Investigational Site Number 1240049
-
Granby, Canada, J2G1T7
- Investigational Site Number 1240005
-
Greenfield Park, Canada, J4V2G8
- Investigational Site Number 1240001
-
Grimsby, Canada, L3M 1P3
- Investigational Site Number 1240046
-
Hamilton, Canada, L8L 2X2
- Investigational Site Number 1240040
-
Hamilton, Canada, L8N 3Z5
- Investigational Site Number 1240037
-
Kingston, Canada, K7L2V7
- Investigational Site Number 1240044
-
Kitchener, Canada, N2N2A8
- Investigational Site Number 1240029
-
Laval, Canada, H7S2M5
- Investigational Site Number 1240013
-
Levis, Canada, G6V3Z1
- Investigational Site Number 1240043
-
Maple Ridge, Canada, V2X5Z6
- Investigational Site Number 1240038
-
Montreal, Canada, H1T1C8
- Investigational Site Number 1240023
-
Montreal, Canada, H3G 1A4
- Investigational Site Number 1240006
-
Montreal, Canada, H4J1C5
- Investigational Site Number 1240008
-
Newmarket, Canada, L3Y8C3
- Investigational Site Number 1240018
-
Niagara Falls, Canada, L2E7H1
- Investigational Site Number 1240012
-
North York, Canada, M2J1W8
- Investigational Site Number 1240020
-
Oshawa, Canada, L1J2J9
- Investigational Site Number 1240015
-
Oshawa, Canada
- Investigational Site Number 1240036
-
Ottawa, Canada, K1Y4W7
- Investigational Site Number 1240024
-
Ottawa, Canada, K2G3M8
- Investigational Site Number 1240032
-
Red Deer, Canada, T4N4E7
- Investigational Site Number 1240056
-
Saskatoon, Canada, S7N0W8
- Investigational Site Number 1240053
-
Scarborough, Canada, M1E5E9
- Investigational Site Number 1240016
-
Sherbrooke, Canada, J1H 5N4
- Investigational Site Number 1240027
-
St-Charles Borromee, Canada, J6E6J2
- Investigational Site Number 1240003
-
St-Georges, Canada, G5Y 4T8
- Investigational Site Number 1240007
-
St. John, Canada, E2L 4L2
- Investigational Site Number 1240041
-
Ste-Foy, Canada, G1V4G5
- Investigational Site Number 1240002
-
Sudbury, Canada, P3C5K7
- Investigational Site Number 1240021
-
Sudbury, Canada, P3E2N8
- Investigational Site Number 1240039
-
Toronto, Canada, M4N3M5
- Investigational Site Number 1240025
-
Toronto, Canada, M5C 2T2
- Investigational Site Number 1240011
-
Toronto, Canada, M5G2C4
- Investigational Site Number 1240019
-
Trois-Rivières, Canada, G8Z 4K4
- Investigational Site Number 1240009
-
Vancouver, Canada, V5Z1M6
- Investigational Site Number 1240047
-
Victoria, Canada, V8R4R2
- Investigational Site Number 1240035
-
Willowdale, Canada, M2K2W2
- Investigational Site Number 1240014
-
Windsor, Canada, N8X3N9
- Investigational Site Number 1240051
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Adult patients with persistent AF (current episode at the screening visit >72 hrs and <12 month duration), for whom cardioversion was clinically indicated and planned to reduce symptoms and antiarrhythmic treatment was clinically indicated to reduce the risk of cardiovascular hospitalization due to AF.
Exclusion criteria:
- Severe congestive heart failure (NYHA Class IV) and other unstable hemodynamic conditions;
- Bradycardia <50 bpm;
- QTc Bazett interval ≥500 ms;
- Second- or third- degree atrio-ventricular (AV) block, or sick sinus syndrome (except when used in conjunction with a functioning pacemaker);
- Severe hepatic impairment;
- Pregnancy and lactation;
- History of hypersensitivity reactions to dronedarone or any of its excipients or component of the container.
Concomitant drugs:
- Antiarrhythmic drugs (AADs) other than dronedarone should not be administered during the study and should be withdrawn for at least five plasma half-lives prior to the first study drug administration;
- Dronedarone should not be co-administered with strong CYP3A4 inhibitors;
- Dronedarone should not be co-administered with drugs inducing torsades de pointes.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dronedarone pre-cardioversion
Dronedarone 400 mg twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
|
Film-coated tablet Oral administration under fed conditions (during breakfast and dinner)
Other Names:
|
Placebo Comparator: Placebo pre-cardioversion
Placebo (for dronedarone) twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
|
Film-coated tablet Oral administration under fed conditions (during breakfast and dinner)
Other Names:
film-coated tablet strictly identical in appearance Oral administration under fed conditions (during breakfast and dinner) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of participants with at least one symptomatic, ECG confirmed, AF recurrence
Time Frame: 6 months from initial cardioversion
|
6 months from initial cardioversion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Symptomatic AF Recurrences/Patient/6 Months (With or Without ECG Confirmation)
Time Frame: up to 6 months from initial cardioversion
|
up to 6 months from initial cardioversion
|
Characteristics of Symptomatic AF Recurrence (Frequency, Duration of Episodes, Type, Number, and Severity of AF Symptoms)
Time Frame: up to 6 months from initial cardioversion
|
up to 6 months from initial cardioversion
|
Proportion of Participants With Early Recurrence of AF (i.e. From 5 Minutes to to 7 Days Following Cardioversion)
Time Frame: up to 7 days following initial cardioversion
|
up to 7 days following initial cardioversion
|
Proportion of Participants With Symptomatic AF Recurrences (With or Without ECG Confirmation)
Time Frame: up to 6 months from initial cardioversion
|
up to 6 months from initial cardioversion
|
Number of Electrical Cardioversions Per Patient
Time Frame: up to 6 months from intial cardioversion
|
up to 6 months from intial cardioversion
|
Number of Shocks Required During Initial Cardioversion
Time Frame: during the initial cardioversion
|
during the initial cardioversion
|
Cumulative Amount of Energy Delivered and Shock Failure
Time Frame: during the initial cardioversion
|
during the initial cardioversion
|
Proportion of Participants With Immediate Recurrence of AF (From 5 Seconds to 5 Minutes After Electrical Shock)
Time Frame: during the initial cardioversion
|
during the initial cardioversion
|
Number of CV Hospitalizations
Time Frame: up to 6 months from initial cardioversion
|
up to 6 months from initial cardioversion
|
Quality of Life, as Measured by Atrial Fibrillation Severity Scale (AFSS) and Atrial Fibrillation Effect on Quality of Life (AFEQT) Questionnaires
Time Frame: Baseline and 6 months after initial cardioversion
|
Baseline and 6 months after initial cardioversion
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DRONE_L_04742
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Dronedarone
-
Rabin Medical CenterUnknownICD | ICD SHOCKS | DRONEDARONE
-
SanofiTerminatedAtrial FibrillationUnited States, Canada
-
SanofiTerminatedAtrial FibrillationUnited States, France, Canada, Brazil, Romania, Russian Federation, Ukraine, Australia, Netherlands, Spain, Sweden, Switzerland, Bulgaria, Malaysia, Singapore, Slovakia, Taiwan, Belgium, Czech Republic, Argentina, Austria, Denmark, ... and more
-
University of UtahSanofiCompletedAtrial Fibrillation
-
SanofiTerminatedCongestive Heart FailurePoland, Netherlands, Sweden, Denmark, Hungary, Norway
-
SanofiCompletedAtrial Fibrillation | Atrial FlutterUnited States, Canada, Argentina, South Africa, Australia
-
SanofiCompletedAtrial FibrillationFrance, Poland, Italy, Netherlands, Spain, Sweden, Switzerland, Belgium, Czech Republic
-
SanofiCompletedAtrial Fibrillation | Atrial FlutterFrance, Poland, Germany, Italy, Netherlands, Spain, Belgium, Czech Republic, United Kingdom, Denmark, Finland, Hungary
-
SanofiCompletedAtrial Fibrillation | Atrial FlutterUnited States, Canada, Poland, Russian Federation, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Turkey, India, Malaysia, Philippines, Singapore, Taiwan, Belgium, Czech Republic, Mexico, Tunisia, Argentina, Finland, Hungary, I... and more
-
SanofiCompleted